title: [Symptomatic high chromogranin A level associated with rabeprazole and ranitidine].
authors.affiliation: Service de Médecine Interne C, CHU Carémeau, Nimes, France.
authors.forename: Thibaut
authors.initials: T
authors.lastname: Fraisse
authors.forename: Julie
authors.initials: J
authors.lastname: Pochic
authors.forename: Véronique
authors.initials: V
authors.lastname: Pinzani
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Balducchi
authors.forename: Erik
authors.initials: E
authors.lastname: Arnaud
authors.forename: Benoît
authors.initials: B
authors.lastname: de Wazières
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000897:Anti-Ulcer Agents / Q000009:adverse effects; D001562:Benzimidazoles / Q000009:adverse effects*; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives*; D064750:Rabeprazole; D011899:Ranitidine / Q000009:adverse effects*; D013276:Stomach Ulcer / Q000188:drug therapy*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins; D064750:Rabeprazole; D011899:Ranitidine; D009853:Omeprazole